Increased Risk of Obesity and Metabolic Dysregulation following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study

Abstract

Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment. These data emphasize the importance of regular monitoring for early identification and treatment of metabolic side effects.